Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 194

Similar articles for PubMed (Select 20005381)

1.

Mycophenolate mofetil versus enteric-coated mycophenolate sodium after simultaneous pancreas-kidney transplantation.

Rangel EB, Melaragno CS, Sá JR, Gonzalez AM, Linhares MM, Salzedas A, Medina-Pestana JO.

Transplant Proc. 2009 Dec;41(10):4265-9. doi: 10.1016/j.transproceed.2009.09.060.

PMID:
20005381
2.

Mycophenolate mofetil versus enteric-coated mycophenolate sodium: a large, single-center comparison of dose adjustments and outcomes in kidney transplant recipients.

Sollinger HW, Sundberg AK, Leverson G, Voss BJ, Pirsch JD.

Transplantation. 2010 Feb 27;89(4):446-51. doi: 10.1097/TP.0b013e3181ca860d.

PMID:
20177347
3.

Comparison of the exposure of mycophenolate mofetil and enteric-coated mycophenolate sodium in recipients of kidney-pancreas transplantation.

Belliere J, Esposito L, Gandia P, Duffas JP, Sallusto F, Cardeau-Desangles I, Del Bello A, Rostaing L, Kamar N.

Ann Transplant. 2014 Feb 10;19:76-81. doi: 10.12659/AOT.889691.

4.

Gastrointestinal quality of life improvement of renal transplant recipients converted from mycophenolate mofetil to enteric-coated mycophenolate sodium drugs or agents: mycophenolate mofetil and enteric-coated mycophenolate sodium.

Ortega F, Sánchez-Fructuoso A, Cruzado JM, Gómez-Alamillo JC, Alarcón A, Pallardó L, Morales JM, Oliver J, Guinea G; MYVIDA Study Group.

Transplantation. 2011 Aug 27;92(4):426-32. doi: 10.1097/TP.0b013e31822527ca.

PMID:
21760569
5.

Superior efficacy of enteric-coated mycophenolate vs mycophenolate mofetil in de novo transplant recipients: pooled analysis.

Salvadori M, Bertoni E, Budde K, Holzer H, Civati G, Lien B, Arns W.

Transplant Proc. 2010 May;42(4):1325-8. doi: 10.1016/j.transproceed.2010.03.044.

PMID:
20534293
6.

Comparing outcomes associated with dose manipulations of enteric-coated mycophenolate sodium versus mycophenolate mofetil in renal transplant recipients.

Cooper M, Deering KL, Slakey DP, Harshaw Q, Arcona S, McCann EL, Rasetto FA, Florman SS.

Transplantation. 2009 Aug 27;88(4):514-20. doi: 10.1097/TP.0b013e3181b0e65e.

PMID:
19696634
7.

Enteric-coated mycophenolate sodium: safe conversion from mycophenolate mofetil in maintenance renal transplant recipients.

Budde K, Glander P, Diekmann F, Dragun D, Waiser J, Fritsche L, Neumayer HH.

Transplant Proc. 2004 Mar;36(2 Suppl):524S-527S.

PMID:
15041401
8.
9.

Evaluation of tolerability and ability to increase immunosuppression in renal transplant patients converted from mycophenolate mofetil to enteric-coated mycophenolate sodium.

Bilodeau JF, Montambault P, Wolff JL, Lemire J, Masse M.

Transplant Proc. 2009 Nov;41(9):3683-9. doi: 10.1016/j.transproceed.2009.06.183.

PMID:
19917367
10.

Stable renal transplant recipients can be safely converted from MMF to enteric-coated mycophenolate sodium tablets: Interim results of a multicenter Latin American study.

Abbud-Filho M, Girón F, Hernández E, Juarez F, Liendo C, Novoa P, Toledo M; Myproms Latam Study Group.

Transplant Proc. 2004 Jul-Aug;36(6):1647-9.

PMID:
15350440
11.
12.

Safety assessment of the conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in stable renal transplant recipients.

Massari P, Duro-Garcia V, Girón F, Hernández E, Juárez F, Castro C, Toledo M; myPROMS LatAm Study Group.

Transplant Proc. 2005 Mar;37(2):916-9.

PMID:
15848574
13.
14.

Similar efficacy and safety of enteric-coated mycophenolate sodium (EC-MPS, myfortic) compared with mycophenolate mofetil (MMF) in de novo heart transplant recipients: results of a 12-month, single-blind, randomized, parallel-group, multicenter study.

Kobashigawa JA, Renlund DG, Gerosa G, Almenar L, Eisen HJ, Keogh AM, Lehmkuhl HB, Livi U, Ross H, Segovia J, Yonan N; ERL2401 Heart Study Investigators.

J Heart Lung Transplant. 2006 Aug;25(8):935-41. Epub 2006 Jun 27.

PMID:
16890114
15.

Better mycophenolic acid 12-hour trough level after enteric-coated mycophenolate sodium in patients with gastrointestinal intolerance to mycophenolate mofetil.

Sánchez Fructuoso A, Calvo N, Moreno MA, Giorgi M, Conesa J, Barrientos A.

Transplant Proc. 2007 Sep;39(7):2194-6.

PMID:
17889135
16.

Efficacy and safety of enteric-coated mycophenolate sodium in renal transplant patients with diabetes mellitus: post hoc analyses from three clinical trials.

Pietruck F, Budde K, Salvadori M, Sollinger H, Bourbigot B, Gentil MA, Oppenheimer F.

Clin Transplant. 2007 Jan-Feb;21(1):117-25.

PMID:
17302600
17.

Quality of life in renal transplant recipients following conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium.

Cofan F, Rosich E, Arias M, Torregrosa V, Oppenheimer F, Campistol JM.

Transplant Proc. 2007 Sep;39(7):2179-81.

PMID:
17889130
18.

Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: results of a 1-year study.

Budde K, Curtis J, Knoll G, Chan L, Neumayer HH, Seifu Y, Hall M; ERL B302 Study Group.

Am J Transplant. 2004 Feb;4(2):237-43.

19.
20.

Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients.

Salvadori M, Holzer H, de Mattos A, Sollinger H, Arns W, Oppenheimer F, Maca J, Hall M; ERL B301 Study Groups.

Am J Transplant. 2004 Feb;4(2):231-6.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk